 |
|
A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
Joonhong Sohn, Ju Byung Chae, Sun Young Lee, Soo-Youl Kim, June-Gone Kim
Korean J Ophthalmol. 2010;24(1):29-34. Published online 2010 Feb 5 DOI: https://doi.org/10.3341/kjo.2010.24.1.29
|
|
Citations to this article as recorded by
 Unilateral acute anterior uveitis is associated with ipsilateral changes in the tear fluid proteome that involves the LXR/RXR pathway
Jon Roger Eidet, Øystein Kalsnes Jørstad, Ida G. Fostad, Ole K. Olstad, Ragnhild Ø. Sørland, Morten C. Moe, Goran Petrovski, Milaim Pepaj
Journal of Ophthalmic Inflammation and Infection.2020;[Epub] CrossRef Infection‐driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells
Benoit Maffei, Marc Laverrière, Yongzheng Wu, Sébastien Triboulet, Stéphanie Perrinet, Magalie Duchateau, Mariette Matondo, Robert L Hollis, Charlie Gourley, Jan Rupp, Jeffrey W Keillor, Agathe Subtil
The EMBO Journal.2020;[Epub] CrossRef Transglutaminase 2 in human diseases
Zsuzsa Szondy, Ilma Korponay-Szabó, Robert Király, Zsolt Sarang, Gregory J. Tsay
BioMedicine.2017; 7(3): 15. CrossRef Transglutaminse 2 and EGGL, the Protein Cross-Link Formed by Transglutaminse 2, As Therapeutic Targets for Disabilities of Old Age
William Bains
Rejuvenation Research.2013; 16(6): 495. CrossRef Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis
Annie Lauzier, Martine Charbonneau, Marilène Paquette, Kelly Harper, Claire M Dubois
Arthritis Research & Therapy.2012;[Epub] CrossRef
|